Review of EGFR TKIs in metastatic NSCLC, including ongoing trials

Frontiers in Oncology

Volumn 4 AUG, Issue , 2014, Pages

  Melosky, Barbara ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Afatinib; Dacomitinib; EGFR TKI; Erlotinib; First line therapy; Gefitinib

Indexed keywords

ADENOSINE TRIPHOSPHATE; AFATINIB; CARBOPLATIN; CISPLATIN; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED;

ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER STAGING; DISEASE CONTROL; DRUG SAFETY; GENE MUTATION; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL(TOPIC); PHASE 3 CLINICAL TRIAL(TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RANDOMIZED CLINICAL TRIAL(TOPIC); SHORT SURVEY; SIGNAL TRANSDUCTION; SURVIVAL; TREATMENT OUTCOME;

EID: 84906509503     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00244     Document Type: Short Survey

References (18)

1. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R: Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol 2011, 6(9):1601-1612.
2. Zhang X, Chang A: Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 2008, 5(4):209-217.
3. Sebastian M, Schmittel A, Reck M: First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. European Respiratory Review 2014, 23(131):92-105.
4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D et al: Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2003, 21(12):2237-2246.
5. Kris M, Natale R, Herbst R, Jr TL, Prager D, CP CB, Schiller J, Kelly K, Spiridonidis H, Sandler A et al: A Phase II trial of ZD1839 ('Iressa') in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2). . In: 2002: Proc Am Soc Clin Oncol 21:292a (A1166); 2002.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132.
7. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366(9496):1527-1537.
8. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al: EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science 2004, 304(5676):1497-1500.
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al: Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine 2004, 350(21):2129-2139.
10. Mok TS WY, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M.: Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
11. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
12. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I et al: Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. New England Journal of Medicine 2010, 362(25):2380-2388.
13. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246.
14. Kosaka T, Yamaki E, Mogi A, Kuwano H: Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011, 165214(10):2.
15. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y et al: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13(5):528-538.
16. Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D et al: Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31(27):3342-3350.
17. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY et al: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced nonsmall-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15(2):213-222.
18. Yang JC-H, Sequist LV, Schuler MH, Mok T, Yamamoto N, O'Byrne KJ, Hirsh V, Geater SL, Zhou C, Massey D et al: Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). In: ASCO 2014: J Clin Oncol; 2014.